Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P13674
UPID:
P4HA1_HUMAN
Alternative names:
Procollagen-proline,2-oxoglutarate-4-dioxygenase subunit alpha-1
Alternative UPACC:
P13674; C9JL12; Q15082; Q15083; Q5VSQ5
Background:
Prolyl 4-hydroxylase subunit alpha-1, also known as Procollagen-proline,2-oxoglutarate-4-dioxygenase subunit alpha-1, plays a pivotal role in collagen synthesis. It catalyzes the post-translational formation of 4-hydroxyproline in -Xaa-Pro-Gly- sequences, a critical step in the maturation and stability of collagen molecules.
Therapeutic significance:
Understanding the role of Prolyl 4-hydroxylase subunit alpha-1 could open doors to potential therapeutic strategies. Its essential function in collagen synthesis makes it a potential target for treating disorders related to extracellular matrix abnormalities.